Dova Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
May 28, 2019 16:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company...
Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference
May 20, 2019 07:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., May 20, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the UBS Global...
Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results
May 07, 2019 07:00 ET
|
Dova Pharmaceuticals, Inc.
First Quarter 2019 net product sales of $4.0 million from DOPTELET® (avatrombopag) New marketing campaign launched early in second quarter for the treatment of thrombocytopenia associated with chronic...
Dova Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 7, 2019
April 30, 2019 08:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., April 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, May 7, 2019 at 9:00 a.m. ET to discuss first quarter 2019 financial...
Dova Pharmaceuticals Receives Positive Opinion from CHMP for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
April 29, 2019 07:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Dova Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
April 02, 2019 16:05 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., April 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the H.C....
Dova Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
March 05, 2019 16:45 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., March 05, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company...
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
March 05, 2019 07:00 ET
|
Dova Pharmaceuticals, Inc.
DOPTELET® (avatrombopag) approved May 21, 2018 and launched June 4, 2018 Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 and $7.7 million for the full year ended...
Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
February 19, 2019 16:15 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, March 5, 2019 at 9:00 a.m. ET to discuss fourth quarter and full...
Dova Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 19, 2019 08:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company...